Sermorelin is a polypeptide of 29 amino acids, typically employed in research related to growth hormone deficiency. It is reportedly the bioactive component of (GHRH). Sermorelin peptide is therefore classified as an analog of growth hormone-releasing hormone (GHRH) and was developed to support and maintain certain properties of natural GHRH. It has been  as a diagnostic agent. Sermorelin peptide is currently researched to assess its impact on endogenous growth hormone secretion, but researchers are also investigating its potential to:

– Increase bone density
– Reduce scarring after a heart attack
– Improve renal function
– Reduce seizure activity
– Mitigate onset symptoms of neurological decline

Sermorelin Peptide and Heart Disease

Cardiac remodeling following damage to the cardiomyocyte (muscle) cells is a serious condition and widely researched. Cardiac remodeling often results in scarring in the damaged area after a heart attack.  In 2016, a research study suggested that Sermorelin peptide exposure might potentially reduce post-cardiac remodeling. The study suggested that Sermorelin peptide, while still in preliminary preclincal research phases, may potentially reduce cardiomyocyte cell death, increase the production of extracellular matrix components needed for proper healing and increase the growth of blood vessels into damaged tissue, ultimately reducing the production of substances may cause inflammation.

Sermorelin peptide has been hypothesized as having the potential to improve diastolic function, reduce scar size and increase capillary growth. Current studies are investigating the properties of Sermorelin in other forms of heart disease, such as in the context of heart failure and valvular heart disease.

Sermorelin Peptide and Epilepsy

Gamma-aminobutyric acid (GABA) is a central nervous system signaling molecule considered to reduce the electrical activity of the spinal cord and the overall electrical excitability of the central nervous system. Many antiepileptic compounds have been developed to increase GABA levels in the central nervous system or by binding to GABA receptors and mimicking GABA effects.

In a recent study using murine models of epilepsy, scientists exposed the mice to GHRH analogs, such as Sermorelin peptide, to measure the impact of these analogs on seizure activity. Researchers reported that in the course of the study, the GHRH analog reportedly suppressed the instances of seizures through a possible activation of the GABA receptors.

Sermorelin Peptide and Sleep Cycles

Some research studies theorize that the sleep cycle may be regulated by Orexin, a neurochemical produced by specific neurons in the brain. Studies suggest that the majority of endogenous growth hormone release and activity occur in tandem to sleep cycles, as the intact GHRH axis is necessary for orexin to secrete and function properly. In addition, one study proposed that extrinsic exposure to Sermorelin peptide and other GHRH agonists may increase orexin secretion.

Sermorelin and Muscle Mass, Long Bone Growth

Sermorelin peptide is a growth hormone-releasing hormone derivative that may potentially exert the same activity as naturally produced growth hormone, inducing similar impact such as increasing muscle mass, promoting long bone growth, and reducing adipose tissue. Research into these hypotheses is ongoing, however. Researchers suggest Sermorelin may present a more plentiful and exacting impact, over extrinsic growth hormone exposure or growth hormone supplementation. The main reason cited by researchers in this claim is that Sermorelin appears to be affected by physiological feedback mechanisms which are considered to be unaffected in cases of supplementation of growth hormone (versus an increase in endogenous production) which may lead to downstream physiological concerns in the organism.


NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.


    Your Cart
    Your cart is empty